7.48
+0.11(+1.49%)
Currency In USD
| Previous Close | 7.37 |
| Open | 7.4 |
| Day High | 7.59 |
| Day Low | 7.38 |
| 52-Week High | 18.75 |
| 52-Week Low | 7.09 |
| Volume | 159,046 |
| Average Volume | 438,996 |
| Market Cap | 273.27M |
| PE | -2.38 |
| EPS | -3.14 |
| Moving Average 50 Days | 7.84 |
| Moving Average 200 Days | 12.22 |
| Change | 0.11 |
If you invested $1000 in iTeos Therapeutics, Inc. (ITOS) since IPO date, it would be worth $392.65 as of February 05, 2025 at a share price of $7.48. Whereas If you bought $1000 worth of iTeos Therapeutics, Inc. (ITOS) shares 3 years ago, it would be worth $206.06 as of February 05, 2025 at a share price of $7.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
GlobeNewswire Inc.
Jan 10, 2025 12:00 PM GMT
- Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - EOS-984 Phase 1 monotherapy and PD-1 combination dat
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2025 12:00 PM GMT
WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeut
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
GlobeNewswire Inc.
Dec 12, 2024 1:55 PM GMT
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts- Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carbo